Business ❯ Pharmaceutical Industry ❯ Drug Development

Clinical Trials

Eli Lilly Market Competition Market Analysis Market Impact Regulatory Approval Market Access FDA Approvals FDA Approval Novo Nordisk Regulatory Affairs

5 ARTICLES

22h ago

Lilly Says Foundayo Outperforms Novo’s Oral Semaglutide in Indirect Diabetes Comparison

Lilly’s EASD presentation claims larger weight loss and A1C drops for Foundayo while leaving regulators to judge the limits of indirect trial comparisons.

3 ARTICLES

23h ago

UniQure Shares Collapse After AMT-130 48‑Month Readout Misses Statistical Goal

Stories older than 24h

9 ARTICLES

3w ago

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

7 ARTICLES

3w ago

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

10 ARTICLES

4w ago

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

7 ARTICLES

4w ago

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

11 ARTICLES

last mo.

Moderna and Merck Report First Phase III Win for an mRNA Cancer Vaccine

7 ARTICLES

last mo.

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

3 ARTICLES

2mo ago

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

6 ARTICLES

3mo ago

FDA Grants Priority Review to Ifinatamab Deruxtecan for Pretreated Small Cell Lung Cancer

5 ARTICLES

6mo ago

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

8 ARTICLES

6mo ago

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

5 ARTICLES

8mo ago

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

6 ARTICLES

8mo ago

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

5 ARTICLES

8mo ago

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

8 ARTICLES

9mo ago

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

14 ARTICLES

9mo ago

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Clinical Trials

Lilly Says Foundayo Outperforms Novo’s Oral Semaglutide in Indirect Diabetes Comparison

UniQure Shares Collapse After AMT-130 48‑Month Readout Misses Statistical Goal

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

Moderna and Merck Report First Phase III Win for an mRNA Cancer Vaccine

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

FDA Grants Priority Review to Pfizer’s Talzenna Plus Xtandi for HRR-Altered mCSPC

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

Never miss stories about

Clinical Trials

South Africa Begins National Rollout of Twice‑Yearly HIV Injection

Pfizer’s Elrexfio Posts Phase 3 PFS Win Over Standard Multiple Myeloma Regimen

FDA Grants Priority Review to Ifinatamab Deruxtecan for Pretreated Small Cell Lung Cancer

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Never miss stories about

Clinical Trials